ChiCTR2400093763 版本V1.0 版本创建时间2024/12/11 16:16:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400093763 

最近更新日期:

Date of Last Refreshed on:

2024-12-11 16:16:01 

注册时间:

Date of Registration:

2024-12-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

左心瓣膜术后功能性三尖瓣反流患者再次手术的危险因素分析及手术风险评估模型构建的研究

Public title:

Identification of risk factors and construction of a surgical risk assessment model for reoperation in patients with functional tricuspid regurgitation following left heart valve surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

左心瓣膜术后功能性三尖瓣反流患者再次手术的危险因素分析及手术风险评估模型构建的研究

Scientific title:

Identification of risk factors and construction of a surgical risk assessment model for reoperation in patients with functional tricuspid regurgitation following left heart valve surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张杨杨 

研究负责人:

朱丹; 张杨杨 

Applicant:

Zhang Yangyang 

Study leader:

Zhu Dan; Zhang Yangyang 

申请注册联系人电话:

Applicant telephone:

+86 138 1813 2320

研究负责人电话:

Study leader's
telephone:

+86 138 1813 2320

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangyangyang_wy@vip.sina.com

研究负责人电子邮件:

Study leader's E-mail:

zhangyangyang_wy@vip.sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区淮海西路241号

研究负责人通讯地址:

上海市徐汇区淮海西路241号

Applicant address:

241 Huaihai Road West, Xuhui District, Shanghai

Study leader's address:

241 Huaihai Road West, Xuhui District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学附属胸科医院

Applicant's institution:

Chest Hospital affiliated to Shanghai Jiaotong University

研究负责人所在单位:

上海交通大学附属胸科医院

Affiliation of the Leader:

Chest Hospital affiliated to Shanghai Jiaotong University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

IS24089

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市胸科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Chest Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-12 00:00:00

伦理委员会联系人:

侯旭敏

Contact Name of the ethic committee:

Hou Xumin

伦理委员会联系地址:

上海市徐汇区淮海西路241号

Contact Address of the ethic committee:

241 Huaihai Road West, Xuhui District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 2220 0000

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学附属胸科医院

Primary sponsor:

Chest Hospital affiliated to Shanghai Jiaotong University

研究实施负责(组长)单位地址:

上海市徐汇区淮海西路241号

Primary sponsor's address:

241 Huaihai Road West, Xuhui District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学附属胸科医院

具体地址:

上海市徐汇区淮海西路241号

Institution
hospital:

Chest Hospital affiliated to Shanghai Jiaotong University

Address:

241 Huaihai Road West, Xuhui District, Shanghai

经费或物资来源:

自发

Source(s) of funding:

spontaneous

研究疾病:

左心瓣膜术后功能性三尖瓣返流  

Target disease:

Functional tricuspid regurgitation after left-sided valve surgery

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

汇总分析上海市胸科医院FTR-LSVS患者临床数据(年龄、性别、BMI、心功能、肾功能、营养预后指数、体外循环时间、主动脉阻断时间、TAPSE、肺动脉压等), 明确FTR-LSVS术前危险因素,并建立FTR-LSVS手术风险评估模型。  

Objectives of Study:

A comprehensive analysis will be conducted on the clinical data of patients who underwent functional tricuspid regurgitation with left-sided valve surgery (FTR-LSVS) at Shanghai Chest Hospital . This analysis will encompass variables such as age, sex, BMI, cardiac function, renal function, nutritional prognostic index, cardiopulmonary bypass duration, aortic cross-clamp time, TAPSE, pulmonary artery pressure, among others. The primary objective is to identify preoperative risk factors for FTR-LSVS and to develop a robust risk assessment model for surgical outcomes in FTR-LSVS patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)左心瓣膜手术后(主动脉瓣和(或)二尖瓣术后无明显病变); (2)术后中长期随访中出现中、重度三尖瓣返流或者三尖瓣返流程度较前提高1级以上; (3)年龄18周岁以上,性别不限。

Inclusion criteria

(1) After left heart valve surgery (no obvious lesions after aortic valve and/or mitral valve surgery); (2) Moderate or severe tricuspid regurgitation occurred during the medium and long-term follow-up after surgery, or the degree of tricuspid regurgitation increased by more than 1 level compared with before; (3) Age 18 years old or above, gender is not limited.

排除标准:

1. 首次手术合并先天性心脏病; 2. 器质性TR; 3. 首次手术存在中度及以上TR或同期进行三尖瓣手术的; 4. 首次手术后住院期间发现的中、重度三尖瓣返流; 5. 未规律复查心脏超声; 6. 左心系统瓣膜需要再次外科干预。

Exclusion criteria:

1. First surgery combined with congenital heart disease; 2. Organic tricuspid regurgitation (TR); 3. Moderate or greater TR present during the first surgery or concurrent tricuspid valve surgery; 4. Moderate to severe tricuspid regurgitation detected during hospitalization after the first surgery; 5. Failure to undergo regular follow-up echocardiograms; 6. Requirement for re-intervention on left-sided cardiac valves.

研究实施时间:

Study execute time:

From 2025-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2027-11-30 00:00:00

干预措施:

Interventions:

组别:

病例组

样本量:

600

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海交通大学附属胸科医院 

单位级别:

三甲 

Institution
hospital:

Chest Hospital affiliated to Shanghai Jiaotong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

再次手术死亡率

指标类型:

主要指标

Outcome:

Reoperative mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术前严重并发症

指标类型:

主要指标

Outcome:

Severe preoperative complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

长期死亡率

指标类型:

主要指标

Outcome:

Long-term mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口学信息

指标类型:

次要指标

Outcome:

Demographic information

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

影像学资料

指标类型:

次要指标

Outcome:

Imaging data

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围手术期生化指标

指标类型:

次要指标

Outcome:

Perioperative biochemical indicators

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术类型

指标类型:

次要指标

Outcome:

Type of surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-12-11 16:16:01